Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of PRAX-628 Tablet vs Capsule in Healthy Participants
NCT06840925Phase 1Completed
- Sponsor
- Praxis Precision Medicines
- Start
- Apr 2025
- Primary completion
- Jun 2025
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vormatrigine in epilepsy (2 arms), sponsored by Praxis Precision Medicines. Primary endpoint: Relative bioavailability of single 40 mg oral doses of PRAX-628 tablet as compared to PRAX-628 capsules at 28 days. Started Apr 2025; status: completed.
02
Drugs
vormatrigine
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT06840925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06840925.